Sugammadex

Active substance: sugammadex

INJECTION, SOLUTION · SUGAMMADEX SODIUM 100 mg/mL

United StatesActive

Marketing holder: Lupin Pharmaceuticals, Inc.

Verified 2026-10-09 · openFDA NDC

Composition

Analogues by country

Products with the same active substance registered in other countries.

Country	Products
EU 7	Bridion sugammadex EMEA/H/C/000885 Merck Sharp & Dohme B.V. Sugammadex Adroiq sugammadex sodium EMEA/H/C/006046 Extrovis EU Ltd Sugammadex Amomed sugammadex sodium EMEA/H/C/005935 AOP Orphan Pharmaceuticals GmbH Sugammadex Fresenius Kabi sugammadex sodium EMEA/H/C/005760 Fresenius Kabi Deutschland GmbH Sugammadex Lorien sugammadex sodium EMEA/H/C/006115 LABORATORIOS LORIEN, S.L All products in this country (7)

Country

Products

EU 7

Bridion
sugammadex
EMEA/H/C/000885
Merck Sharp & Dohme B.V.
Sugammadex Adroiq
sugammadex sodium
EMEA/H/C/006046
Extrovis EU Ltd
Sugammadex Amomed
sugammadex sodium
EMEA/H/C/005935
AOP Orphan Pharmaceuticals GmbH
Sugammadex Fresenius Kabi
sugammadex sodium
EMEA/H/C/005760
Fresenius Kabi Deutschland GmbH
Sugammadex Lorien
sugammadex sodium
EMEA/H/C/006115
LABORATORIOS LORIEN, S.L

Import and control

United Statesprescription only
Source: openFDA NDC · record 01a1208c-2b19-7c7b-a46d-69ec47b919f5,01a1208c-3099-7449-9b38-72d02a0caeb2,01a1208c-3dcf-722e-87f8-a6319b9a9a9a,01a1208c-8796-79d5-8114-10213f312eda,01a1208c-9f49-7bc5-8ff9-c1356b503d77;count=44 · valid from 2026-10-09 · verified 2026-10-09